The long‑anticipated TAME (Targeting Aging with Metformin) trial continues to enroll older adults. Metformin, a well‑tolerated diabetes drug, is being tested for its ability to delay the onset of age‑related diseases (cardiovascular disease, cancer, dementia). Results are not yet available, but the trial design has become a model for future aging intervention studies.
A 2025 trial (now published in full) showed that the SGLT2 inhibitor henagliflozin was associated with longer telomeres in diabetic patients after 12 months of treatment. The effect was independent of glycaemic control, suggesting a direct anti‑aging effect. Replication in non‑diabetic populations is needed.
An AI‑driven robotics laboratory identified a TNIK inhibitor as a potent senomorphic agent (suppressing the SASP without killing senescent cells). The compound is now in preclinical development. This validates our proposed direction of AI‑assisted drug discovery for longevity.
Japanese biotech Renascience is developing RS5614, a small molecule inhibitor of PAI‑1, as a potential senolytic. Preclinical data show reduced senescent cell burden in aged mouse kidneys. Human trials are not yet announced.